Anzeige
Mehr »
Montag, 30.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSB5 | ISIN: US60853G1067 | Ticker-Symbol: 6ML0
Siehe auch MOLECULAR PARTNERS AG
Frankfurt
27.06.25 | 21:55
3,040 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MOLECULAR PARTNERS AG ADR Chart 1 Jahr
5-Tage-Chart
MOLECULAR PARTNERS AG ADR 5-Tage-Chart
RealtimeGeldBriefZeit
3,0003,24027.06.

Aktuelle News zur MOLECULAR PARTNERS AG ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiMOLECULAR PARTNERS AG - S-8, Securities to be offered to employees in employee benefit plans5
23.06.Molecular Partners und Partner Orano präsentieren neue Daten zu Radio-DARPin10
22.06.Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025432MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano MedPromising tumor...
► Artikel lesen
MOLECULAR PARTNERS AG ADR Aktie jetzt für 0€ handeln
11.06.Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025602Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 monthsAcceptable safety profile across all cohorts, including...
► Artikel lesen
10.06.Molecular Partners kündigt Personalabbau zur Ausweitung der Liquiditätsreserven an3
10.06.Molecular Partners to cut jobs, cash reach now anticipated to extend into 20285
10.06.Molecular Partners entwickelte Corona-Medikament in Schlieren: Zürcher Biotech-Firma entlässt ein Viertel der Belegschaft4
10.06.Molecular Partners baut einen Viertel der Belegschaft ab361Schlieren - Das Biotech-Unternehmen Molecular Partners tritt auf die Kostenbremse und baut bis zu 40 Arbeitsplätze ab. Ziel sei es, die Effizienz zu steigern, den Fokus stärker auf die Weiterentwicklung...
► Artikel lesen
10.06.Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway385Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025Cash reach now anticipated to extend into 2028 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE)...
► Artikel lesen
19.05.Molecular Partners to Present at Upcoming Investor Conferences431ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
16.05.Molecular Partners reports Q1 results2
15.05.Molecular Partners Reports Financial Results and Highlights from Q1 2025545Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinical...
► Artikel lesen
15.05.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer3
29.04.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer8
25.04.Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025572Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel...
► Artikel lesen
16.04.Molecular Partners Announces all Board Proposals Approved at Annual General Meeting495ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
25.03.Molecular Partners to hold three poster presentations at AACR 20251.355Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First...
► Artikel lesen
25.03.Molecular Partners Publishes Invitation to Annual General Meeting 2025476ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
14.03.TD Cowen maintains Buy on Molecular Partners, target CHF1510
06.03.Molecular Partners GAAP EPS of -CHF1.59, revenue of CHF5.0M1
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1